CellaVision (CEVI.ST) Stock Price
CellaVision Price
Over the last 19 years CellaVision grew revenue by 14.8% annually, reaching 758.97 M SEK. Earnings per share have grown at 25.3% per year over the last 18 years. For CellaVision, the net margin of 20.2% is down versus 22.2% a few years ago. At today's price the dividend yield works out to roughly 1.25%. The payout ratio is around 39% of earnings. The dividend has grown at 15.1% per year over the past 13 years. The consensus 12-month price target for CellaVision is 232.56 SEK, about 16.3% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
CellaVision stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
CellaVision business model & stock analysis
Frequently asked questions about CellaVision
The business model of CellaVision AB focuses on developing and selling digital solutions for medical laboratories worldwide. CellaVision offers an innovative range of products, including automated digital systems for advanced blood cell analysis and software solutions for efficient lab management. The company's solutions aim to improve lab productivity, quality, and patient care by streamlining workflow processes and enhancing the accuracy of blood cell analysis. CellaVision AB stands as a leading provider in the field of hematology diagnostics, enabling healthcare professionals to make better-informed decisions for optimizing patient outcomes.
CellaVision AB is primarily active in the medical technology industry.
The main competitors of CellaVision AB in the market include Sysmex Corporation, Roche Diagnostics, and Beckman Coulter.
CellaVision AB is a leading global provider of advanced digital solutions for medical microscopy in the field of hematology. Founded in 1994, CellaVision has a rich history in developing and supplying innovative products that revolutionize the analysis of blood and other body fluids. The company's breakthrough technologies enable automated digital microscopy, accelerating and improving the diagnostic workflow in clinical laboratories. CellaVision's solutions offer healthcare professionals increased efficiency, accuracy, and patient safety, ultimately contributing to better healthcare outcomes. With a strong commitment to research and development, CellaVision continues to pioneer advancements in digital hematology, establishing itself as a trusted name in the industry.
CellaVision AB, a renowned company in the stock market, has achieved several significant milestones throughout its journey. These include the development and launch of cutting-edge hematology analyzers, such as the CellaVision DM96 and CellaVision DC-1. The company has also expanded its global presence, establishing strategic partnerships with various leading healthcare organizations worldwide. Furthermore, CellaVision AB has consistently demonstrated its commitment to innovation by continuously enhancing its product portfolio and introducing advanced digital solutions in the field of automated blood and body fluid analysis. With its relentless pursuit of excellence and industry recognition, CellaVision AB stands as a remarkable player in the stock market.
CellaVision AB is primarily present in various countries and regions around the world. With its global reach, the company has established its presence in countries such as Sweden, the United States, and various European and Asian markets. CellaVision AB's extensive global footprint allows it to cater to a diverse customer base and expand its market share internationally.
CellaVision AB represents a set of core values and a corporate philosophy that underpin its operations. The company is committed to excellence, innovation, and customer satisfaction. Through its cutting-edge technologies and solutions, CellaVision aims to revolutionize hematology analysis and improve patient care. With a focus on quality, CellaVision strives to deliver accurate and reliable results, empowering healthcare professionals worldwide. Moreover, the company fosters a culture of collaboration, teamwork, and transparency to drive advancements in the field of medical diagnostics. By embodying these values, CellaVision AB remains dedicated to its mission of transforming healthcare through intelligent automation and efficient laboratory workflows.
Analysts currently set an average price target of 223.72 SEK for the CellaVision stock (median: 232.56 SEK), implying +11.9 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the CellaVision stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect CellaVision to generate revenue of 784.20 M SEK and earnings per share of 6.25 SEK.
Converted at the current exchange rate, the CellaVision share trades at 18.15 EUR (200.00 SEK).
The CellaVision share (CEVI.ST) is listed on 5 stock exchanges, including: London (0MR5.L), Frankfurt (C26.F), München (C26.MU), Stockholm (CEVI.ST).
CellaVision AB is a leading provider of digital solutions for automated blood cell analysis. The company, based in Lund, Sweden, was founded in 1994 and now employs over 350 people.
The expected revenue of CellaVision is 784.20 M SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of CellaVision is 149.09 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of CellaVision is currently 32.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CellaVision stock.
The price-to-sales ratio (P/S) of CellaVision is currently 6.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CellaVision stock.
The Eulerpool Quality Score for CellaVision is 9/10.
The ISIN of CellaVision is SE0000683484. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of CellaVision is A0NEVD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of CellaVision is CEVI.ST. The ticker symbol is used to trade CellaVision shares on the stock exchange.
CellaVision stock
CellaVision Peer Group
CellaVision Ticker
CellaVision FIGI
All fundamentals and in-depth analysis of CellaVision
Our stock analysis for CellaVision stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CellaVision. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.